Isolation and characterisation of equine influenza viruses (H3N8) from Europe and North America from 2008 to 2009

Like other influenza A viruses, equine influenza virus undergoes antigenic drift. It is therefore essential that surveillance is carried out to ensure that recommended strains for inclusion in vaccines are kept up to date. Here we report antigenic and genetic characterisation carried out on equine influenza virus strains isolated in North America and Europe over a 2-year period from 2008 to 2009. Nasopharyngeal swabs were taken from equines showing acute clinical signs and submitted to diagnostic laboratories for testing and virus isolation in eggs. The sequence of the HA1 portion of the viral haemagglutinin was determined for each strain. Where possible, sequence was determined directly from swab material as well as from virus isolated in eggs. In Europe, 20 viruses were isolated from 15 sporadic outbreaks and 5 viruses were isolated from North America. All of the European and North American viruses were characterised as members of the Florida sublineage, with similarity to A/eq/Lincolnshire/1/07 (clade 1) or A/eq/Richmond/1/07 (clade 2). Antigenic characterisation by haemagglutination inhibition assay indicated that the two clades could be readily distinguished and there were also at least seven amino acid differences between them. The selection of vaccine strains for 2010 by the expert surveillance panel have taken these differences into account and it is now recommended that representatives of both Florida clade 1 and clade 2 are included in vaccines.     

Upper Respiratory Disease in Thoroughbred Horses: studies of its viral etiology in the Toronto area, 1960 to 1963

From outbreaks of upper respiratory infection of horses in the Toronto area between 1960 and 1963, several viruses have been isolated. The viruses, isolated in tissue cultures or eggs, include an equine strain of Myxovirus parainfluenzae 3; two strains of equine influenza virus, A/equi-1/Prague/56, and A/equi-2/Miami/63; equine rhinopneumonitis virus, and two newly recognized viruses of the horse, equine rhinoviruses. In addition serological evidence suggested a widespread infection with these viruses in the population under study. Because of the identical clinical picture seen and the complex etiology of the disease, immunization against upper respiratory disease of the horse does not appear to be completely feasible at this time.     

An Outbreak of Type A2 Influenza Among Horses

The clinical diagnosis of equine influenza was first based on the spectacular contagiousness of the disease, the general clinical resemblances to human influenza and the almost complete absence of complications usually observed in infectious viral arteritis, viral rhinopneumonitis or in other respiratory infections of the horses. The specific viral etiology of the epizootic was ascertained through the isolation of a type A influenza virus and further substantiated by evaluation of the immunological response of the sick horses, as demonstrated by complement fixation and hemagglutination-inhibition tests, using normal and convalescent sera.     

Emergence of H3N2 reassortant influenza A viruses in North American pigs

In late summer through early winter of 1998, there were several outbreaks of respiratory disease in the swine herds of North Carolina, Texas, Minnesota and Iowa. Four viral isolates from outbreaks in different states were analyzed, both antigenically and genetically. All of the isolates were identified as H3N2 influenza viruses with antigenic profiles similar to those of recent human H3 strains. Genotyping and phylogenetic analysis demonstrated that the four swine viruses had emerged through two different pathways. The North Carolina isolate is the product of genetic reassortment between human and swine influenza viruses, while the others arose from reassortment of human, swine and avian viral genes. The hemagglutinin genes of the four isolates were all derived from the human H3N2 virus circulating in 1995. It remains to be determined if either of these recently emerged viruses will become established in the pigs in North America and whether they will become an economic burden.     

1. Isolation and Characterisation of Equine Rhinopneumontis Virus and Other Equine Herpesviruses from Horses

Equine herpesviruses (EH viruses) were isolated from 9 horses in three separate outbreaks of respiratory disease. The pattern of disease in the three stables is described and evidence is presented that some of the horses were ill, possibly as a result of recurrent infection, and that reactivation of a persistent, latent infection may have occurred. An ulcerative condition of the pharyngeal region was seen in some of the horses with EH virus infection.
The cytopathogenicity for equine foetal kidney cells of the 9 EH viruses varied considerably. One isolate, EH 39 virus, which was recovered from an acute, upper respiratory tract infection, was rapidly cytopathic for equine foetal kidney cell cultures and was shown in neutralisation tests to be identical with, or closely related to equine rhinopneumonitis virus (EH virus type 1) that is associated with acute respiratory disease and abortion in other countries. More slowly cytopathic isolates were recovered from mild to subclinical upper respiratory tract infections. Evidence is presented that the property of slow cytopathogenicity is probably related to the tendency of these viruses to remain cell associated. Slowly cytopathic isolates were recovered from the nasal cavity of horse 89 on two occasions 79 days apart. One of the eight slowly cytopathic isolates, EH 86 virus, was shown to be antigenically distinct from equine rhinopneumonitis virus (EH 39 virus).     

猪流感病毒血凝素基因的研究进展

猪流感是由猪流感病毒引起的一种急性、热性、高度接触传染性呼吸道疾病,可继发和并发多种细菌病和病毒病,已日益成为危害世界猪群的主要传染病之一。猪流感病毒血凝素基因作为流感病毒表面最主要的抗原基因,其表达蛋白具有丰富的生物学作用,对流感病毒的致病性起着主导作用。作者主要对猪流感病毒血凝素基因的研究进行了综述,为进一步防治猪流感及开发新型疫苗提供帮助。     

2007年华北地区H3N8亚型马流感病毒的分离与鉴定

2007年10月,华北地区某赛马场的马同时发生了以发烧、流水样鼻汁或脓性分泌物、咳嗽等临床症状为主的疾病,疑似马流行性感冒。采集患病赛马的鼻腔分泌物,发病期和发病后14d血清,经鸡胚接种法分离病毒,并用鸡红细胞血凝抑制试验(HI)、神经氨酸酶抑制试验(NI)、病毒回归试验、血清学检测和基因序列分析对分离的病毒进行了系统鉴定。结果表明分离的毒株(A/equine/Huabei/1/2007(H3N8)为马源H3N8亚型马流感病毒,基因型属于美洲分支。我们通过动物回归感染试验建立起分离毒株的实验感染模型。     

Comparison of two modern vaccines and previous influenza infection against challenge with an equine influenza virus from the Australian 2007 outbreak

During 2007, large outbreaks of equine influenza (EI) caused by Florida sublineage Clade 1 viruses affected horse populations in Japan and Australia. The likely protection that would be provided by two modern vaccines commercially available in the European Union (an ISCOM-based and a canarypox-based vaccine) at the time of the outbreaks was determined. Vaccinated ponies were challenged with a representative outbreak isolate (A/eq/Sydney/2888-8/07) and levels of protection were compared. A group of ponies infected 18 months previously with a phylogenetically-related isolate from 2003 (A/eq/South Africa/4/03) was also challenged with the 2007 outbreak virus. After experimental infection with A/eq/Sydney/2888-8/07, unvaccinated control ponies all showed clinical signs of infection together with virus shedding. Protection achieved by both vaccination or long-term immunity induced by previous exposure to equine influenza virus (EIV) was characterised by minor signs of disease and reduced virus shedding when compared with unvaccinated control ponies. The three different methods of virus titration in embryonated hens’ eggs, EIV NP-ELISA and quantitative RT-PCR were used to monitor EIV shedding and results were compared. Though the majority of previously infected ponies had low antibody levels at the time of challenge, they demonstrated good clinical protection and limited virus shedding. In summary, we demonstrate that vaccination with current EIV vaccines would partially protect against infection with A/eq/Sydney/2888-8/07-like strains and would help to limit the spread of disease in our vaccinated horse population.     

Recombinant viruses of poultry as vector vaccines against fowl plague

To help in the control of fowl plague caused by highly pathogenic avian influenza A viruses of hemagglutinin (HA) subtypes H5 and H7 several vaccines have been developed. A prophylactic immunization of poultry with inactivated influenza viruses in non-endemic situations is questionable, however, due to the impairment of serological identification of field virus-infected animals which hinders elimination of the infectious agent from the population. This problem might be overcome by the use of genetically engineered marker vaccines which contain only the protective influenza virus hemagglutinin. Infected animals could then be unambiguously identified by their serum antibodies against other influenza virus proteins, e.g. neuraminidase or nucleoprotein. For such a use, purified HA or HA-expressing DNA vaccines are conceivable. Economically advantageous and easier to apply are modified live virus vaccines in use against other poultry diseases, which have been modified to express influenza virus HA. So far, recombinant HA-expressing fowlpox virus (FPV) as well as infectious laryngotracheitis and Newcastle disease viruses have been asssessed in animal experiments. An H5-expressing FPV recombinant is already in use in Central America and Southeast Asia but without accompanying marker diagnostics. Advantages and disadvantages of the different viral vectors are discussed.     

Equine Respiratory Disease on the Western Canadian Racetracks

The serological results from this study clearly show that both equine influenza and equine rhinopneumonitis viruses were present during spring and autumn epidemics of respiratory disease on Western Canadian racetracks. Approximately 11% of the horses showed significant convalescent titres to influenza while 9% showed significant convalescent titres for equine viral pneumonitis. It was noted in our study a positive vaccination history corresponded with a reduction in the severity of the respiratory infection.     

Current perspectives on control of equine influenza

Influenza A viruses of the H3N8 subtype are a major cause of respiratory disease in horses. Subclinical infection with virus shedding can occur in vaccinated horses, particularly where there is a mismatch between the vaccine strains and the virus strains circulating in the field. Such infections contribute to the spread of the disease. Rapid diagnostic techniques are available for detection of virus antigen and can be used as an aid in control programmes. Improvements have been made to methods of standardising inactivated virus vaccines, and a direct relationship between vaccine potency measured by single radial diffusion and vaccine-induced antibody measured by single radial haemolysis has been demonstrated. Improved adjuvants and antigenic presentation systems extend the duration of immunity induced by inactivated virus vaccines, but high levels of antibody are required for protection against field infection. In addition to circulating antibody, infection with influenza virus stimulates mucosal and cellular immunity; unlike immunity to inactivated virus vaccines, infection-induced immunity is not dependent on the presence of circulating antibody to HA. Live attenuated or vectored equine influenza vaccines, which may better mimic the immunity generated by influenza infection than inactivated virus vaccines, are now available. Mathematical modelling based upon experimental and field data has been applied to examine issues relating to vaccine efficacy at the population level. A vaccine strain selection system has been implemented and a more global approach to the surveillance of equine influenza is being developed.     

Infectious diseases of New-World camelids (NWC)

Although there are notable infectious conditions that are capable of producing clinical disease in the NWC, overall, these species are quite healthy. Of the bacterial diseases, enterotoxemia caused by Clostridium perfringens types C and D would be deemed the most significant in North America, while type A also would be regarded as important in South America. Other important bacterial infections of potential concern are tuberculosis, Johne's disease, anthrax, malignant edema, actinomycosis, tetanus, and the South American condition referred to as alpaca fever, which, to date, has not been observed in North America. Fungal infections include classical ringworm, principally caused by Trichophyton spp., and the cases of coccidioidomycosis that are associated with the arid desert lands of the southwestern United States. Most notable of naturally occurring viral infections in the NWC would be rabies, ecthyma, and a recently described blindness neuropathy that has been associated with the equine herpesvirus I. NWC can be infected experimentally with agents causing hoof-and-mouth disease and vesicular stomatitis, but naturally occurring cases do not seem to occur. Serological evidence of exposure to many viral agents, including blue tongue, parainfluenza 3, bovine respiratory syncytial virus, bovine herpesvirus I, bovine viral diarrhea, influenza A, and rotavirus, has been demonstrated; however, no clinical disease associated with these agents, as yet, is apparent.     

马鼻肺炎诊断方法研究进展

马鼻肺炎的病原是马疱疹病毒l型和马疱疹病毒4型,属于疱疹病毒目,疱疹病毒科,a疱疹病毒亚科,通常会引起呼吸道疾病和病毒性流产,严重时引发神经性疾病。该病毒在世界范围内流行,对养马业和赛马业的危害很大。本文总结国内外近些年关于马疱疹病毒的病原学和血清学诊断方法的研究成果,了解国际上关于马鼻肺炎检测诊断方法的研究进展,为出入境赛马的马鼻肺炎的检验检疫提供可靠的检测方法。     

Antigenic and genetic variations in European and North American equine influenza virus strains (H3N8) isolated from 2006 to 2007

Equine influenza virus (EIV) surveillance is important in the management of equine influenza. It provides data on circulating and newly emerging strains for vaccine strain selection. To this end, antigenic characterisation by haemaggluttination inhibition (HI) assay and phylogenetic analysis was carried out on 28 EIV strains isolated in North America and Europe during 2006 and 2007. In the UK, 20 viruses were isolated from 28 nasopharyngeal swabs that tested positive by enzyme-linked immunosorbent assay. All except two of the UK viruses were characterised as members of the Florida sublineage with similarity to A/eq/Newmarket/5/03 (clade 2). One isolate, A/eq/Cheshire/1/06, was characterised as an American lineage strain similar to viruses isolated up to 10 years earlier. A second isolate, A/eq/Lincolnshire/1/07 was characterised as a member of the Florida sublineage (clade 1) with similarity to A/eq/Wisconsin/03. Furthermore, A/eq/Lincolnshire/1/06 was a member of the Florida sublineage (clade 2) by haemagglutinin (HA) gene sequence, but appeared to be a member of the Eurasian lineage by the non-structural gene (NS) sequence suggesting that reassortment had occurred. A/eq/Switzerland/P112/07 was characterised as a member of the Eurasian lineage, the first time since 2005 that isolation of a virus from this lineage has been reported. Seven viruses from North America were classified as members of the Florida sublineage (clade 1), similar to A/eq/Wisconsin/03. In conclusion, a variety of antigenically distinct EIVs continue to circulate worldwide. Florida sublineage clade 1 viruses appear to predominate in North America, clade 2 viruses in Europe.     

Disseminated necrotizing myeloencephalitis: a herpes-associated neurological disease of horses.

Equine viral rhinopneumonitis type I virus was isolated from spinal cord and brain of a paraparetic horse with disseminated necrotizing myeloencephalitis. Necrotic arteriolitis,nonsuppurative necrotizing myeloencephalitis and Gasserian ganglioneuritis were present. On record were 12 more cases of horses with similar lesions. The horses had been ataxic or paretic for up to several weeks. A field survey indicated that 14 of 24 horses with acute myelitic signs developed them after recent exposure to respiratory disease.     

Pandemic H1N1 influenza virus in Chilean commercial turkeys with genetic and serologic comparisons to U.S. H1N1 avian influenza vaccine isolates

Beginning in April 2009, a novel H1N1 influenza virus caused acute respiratory disease in humans, first in Mexico and then around the world. The resulting pandemic influenza A H1N1 2009 (pH1N1) virus was isolated in swine in Canada in June 2009 and later in breeder turkeys in Chile, Canada, and the United States. The pH1N1 virus consists of gene segments of avian, human, and swine influenza origin and has the potential for infection in poultry following exposure to infected humans or swine. We examined the clinical events following the initial outbreak of pH1N1 in turkeys and determined the relatedness of the hemagglutinin (HA) gene segments from the pH1N1 to two H1N1 avian influenza (AI) isolates used in commercial turkey inactivated vaccines. Overall, infection of turkey breeder hens with pH1N1 resulted in -50% reduction of egg production over 3-4 weeks. Genetic analysis indicated one H1N1 AI vaccine isolate (Alturkey/North Carolina/17026/1988) contained approximately 92% nucleotide sequence similarity to the pH1N1 virus (A/Mexico/4109/2009); whereas, a more recent AI vaccine isolate (A/ swine/North Carolina/00573/2005) contained 75.9% similarity. Comparison of amino acids found at antigenic sites of the HA protein indicated conserved epitopes at the Sa site; however, major differences were found at the Ca2 site between pH1N1 and A/ turkey/North Carolina/127026/1988. Hemagglutinin-inhibition (HI) tests were conducted with sera produced in vaccinated turkeys in North Carolina to determine if protection would be conferred using U.S. AI vaccine isolates. HI results indicate positive reactivity (HI titer > or = 5 log2) against the vaccine viruses over the course of study. However, limited cross-reactivity to the 2009 pH1N1 virus was observed, with positive titers in a limited number of birds (6 out of 20) beginning only after a third vaccination. Taken together, these results demonstrate that turkeys treated with these vaccines would likely not be protected against pH1N1 and current vaccines used in breeder turkeys in the United States against circulating H1N1 viruses should be updated to ensure adequate protection against field exposure.     

Evaluation of the kidney as a potential site of avian influenza virus persistence in chickens.

One-day-old chickens were inoculated intravenously with one of three low-pathogenicity avian-origin influenza isolates. On day 5 postinoculation (PI), the frequency of influenza virus isolation from cloacal swabs following challenge with each isolate ranged from 83% to 100% for clinically normal euthanatized chickens. Influenza virus was also frequently isolated from kidneys of these chickens (47%) and from chickens that died (100%). Kidneys positive for virus isolation had lesions of nephrosis and/or acute nephritis, and influenza viral nucleoprotein was demonstrated in nuclei and cytoplasm of necrotic renal tubule epithelium. On sampling days 28 and 45/60 PI, influenza virus was neither isolated from nor immunohistochemically demonstrated in kidneys (0/125); however, the kidneys (47%) did have chronic histologic lesions that suggested previous influenza virus infection of the kidneys. Influenza virus was isolated from cloacal swabs of two of 44 chickens on day 28 PI, but all cloacal swabs were negative for virus recovery on sampling day 45/60 PI (0/81). These results indicate that replication of influenza virus in renal tubule epithelial cells did not result in persistence of type A influenza virus in this immunologically privileged site.     

Viruses associated with respiratory disease of horses in New Zealand: an update

Viruses causing or associated with respiratory disease in horses worldwide are reviewed. Results are presented from a serological survey of 121 New Zealand foals and horses that had been affected by respiratory disease, determining the prevalence of antibodies in this country to the major viruses associated with similar disease overseas. To date there is no evidence of equine influenza virus in New Zealand. Both equine herpesvirus type 1 and 2 have been frequently isolated and show high serological prevalences. Serological evidence of equine rhinovirus type 1 and type 2 is presented with a prevalence of 12.3% and 41.2% respectively observed in foal sera, and 37.7% and 84.9% in adult horse sera. Antibody reacting to equine viral arteritis virus antigen was detected in 3/121 test sera. Equine adenovirus has been isolated on occasions and has shown a 39% serological prevalence in one study reviewed. Progress in New Zealand equine virus research is discussed.     

Immune responses to commercial equine vaccines against equine herpesvirus-1, equine influenza virus, eastern equine encephalomyelitis, and tetanus

Horses are commonly vaccinated to protect against pathogens which are responsible for diseases which are endemic within the general horse population, such as equine influenza virus (EIV) and equine herpesvirus-1 (EHV-1), and against a variety of diseases which are less common but which lead to greater morbidity and mortality, such as eastern equine encephalomyelitis virus (EEE) and tetanus. This study consisted of two trials which investigated the antigenicity of commercially available vaccines licensed in the USA to protect against EIV, EHV-1 respiratory disease, EHV-1 abortion, EEE and tetanus in horses. Trial I was conducted to compare serological responses to vaccines produced by three manufacturers against EIV, EHV-1 (respiratory disease), EEE, and tetanus given as multivalent preparations or as multiple vaccine courses. Trial II compared vaccines from two manufacturers licensed to protect against EHV-1 abortion, and measured EHV-1-specific interferon-gamma (IFN-gamma) mRNA production in addition to serological evidence of antigenicity. In Trial I significant differences were found between the antigenicity of different commercial vaccines that should be considered in product selection. It was difficult to identify vaccines that generate significant immune responses to respiratory viruses. The most dramatic differences in vaccine performance occurred in the case of the tetanus antigen. In Trial II both vaccines generated significant antibody responses and showed evidence of EHV-1-specific IFN-gamma mRNA responses. Overall there were wide variations in vaccine response, and the vaccines with the best responses were not produced by a single manufacturer. Differences in vaccine performance may have resulted from differences in antigen load and adjuvant formulation.     

Efficacy of a pandemic (H1N1) 2009 virus vaccine in pigs against the pandemic influenza virus is superior to commercially available swine influenza vaccines

In April 2009 a new influenza A/H1N1 strain, currently named "pandemic (H1N1) influenza 2009" (H1N1v), started the first official pandemic in humans since 1968. Several incursions of this virus in pig herds have also been reported from all over the world. Vaccination of pigs may be an option to reduce exposure of human contacts with infected pigs, thereby preventing cross-species transfer, but also to protect pigs themselves, should this virus cause damage in the pig population. Three swine influenza vaccines, two of them commercially available and one experimental, were therefore tested and compared for their efficacy against an H1N1v challenge. One of the commercial vaccines is based on an American classical H1N1 influenza strain, the other is based on a European avian H1N1 influenza strain. The experimental vaccine is based on reassortant virus NYMC X179A (containing the hemagglutinin (HA) and neuraminidase (NA) genes of A/California/7/2009 (H1N1v) and the internal genes of A/Puerto Rico/8/34 (H1N1)). Excretion of infectious virus was reduced by 0.5-3 log(10) by the commercial vaccines, depending on vaccine and sample type. Both vaccines were able to reduce virus replication especially in the lower respiratory tract, with less pathological lesions in vaccinated and subsequently challenged pigs than in unvaccinated controls. In pigs vaccinated with the experimental vaccine, excretion levels of infectious virus in nasal and oropharyngeal swabs, were at or below 1 log(10)TCID(50) per swab and lasted for only 1 or 2 days. An inactivated vaccine containing the HA and NA of an H1N1v is able to protect pigs from an infection with H1N1v, whereas swine influenza vaccines that are currently available are of limited efficaciousness. Whether vaccination of pigs against H1N1v will become opportune remains to be seen and will depend on future evolution of this strain in the pig population. Close monitoring of the pig population, focussing on presence and evolution of influenza strains on a cross-border level would therefore be advisable.